Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Djordje Atanackovic

Showing results (1-10 of 139) with videos related to

Pageof 14
Sort By:
British Journal of Haematology|October 12, 2013
Second autologous transplant as salvage therapy in multiple myelomaDjordje Atanackovic, Georgia Schilling
Seminars in Cancer Biology|May 19, 2018
Biomarkers for checkpoint inhibition in hematologic malignanciesDjordje Atanackovic, Tim Luetkens
European Journal of Cancer (Oxford, England : 1990)|September 28, 2011
Current standards and new trends in the primary treatment of colorectal cancerAlexander Stein, Djordje Atanackovic, Carsten Bokemeyer
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 27, 2013
Immune-modulating drugs and hypomethylating agents to prevent or treat relapse after allogeneic stem cell transplantationNicolaus Kröger, Thomas Stübig, Djordje Atanackovic
Journal of Hematopathology|June 12, 2024
Carvykti CAR T-cell morphology in cellavision peripheral smear reviewsMichael E Kallen, Rima Koka, Djordje Atanackovic
European Journal of Haematology|December 29, 2019
B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta-analysisNico Gagelmann, Francis Ayuk, Djordje Atanackovic, et al.
Current Cancer Drug Targets|September 7, 2017
Coinhibitory Molecule PD-1 as a Therapeutic Target in the Microenvironment of Multiple MyelomaDjordje Atanackovic, Tim Luetkens, Sabari Radhakrishnan, et al.
British Journal of Haematology|January 22, 2016
Chimeric Antigen Receptor (CAR) therapy for multiple myelomaDjordje Atanackovic, Sabarinath V Radhakrishnan, Neelam Bhardwaj, et al.
Clinical Immunology (Orlando, Fla.)|October 17, 2018
The role of surface molecule CD229 in Multiple MyelomaMichael Olson, Sabarinath Venniyil Radhakrishnan, Tim Luetkens, et al.
Oncoimmunology|June 23, 2017
Novel anti-myeloma immunotherapies targeting the SLAM family of receptorsSabarinath Venniyil Radhakrishnan, Neelam Bhardwaj, Tim Luetkens, et al.
Pageof 14

Showing results (1-10 of 139) with videos related to

Sort By:
Pageof 14
British Journal of Haematology|October 12, 2013
Second autologous transplant as salvage therapy in multiple myelomaDjordje Atanackovic, Georgia Schilling
Seminars in Cancer Biology|May 19, 2018
Biomarkers for checkpoint inhibition in hematologic malignanciesDjordje Atanackovic, Tim Luetkens
European Journal of Cancer (Oxford, England : 1990)|September 28, 2011
Current standards and new trends in the primary treatment of colorectal cancerAlexander Stein, Djordje Atanackovic, Carsten Bokemeyer
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 27, 2013
Immune-modulating drugs and hypomethylating agents to prevent or treat relapse after allogeneic stem cell transplantationNicolaus Kröger, Thomas Stübig, Djordje Atanackovic
Journal of Hematopathology|June 12, 2024
Carvykti CAR T-cell morphology in cellavision peripheral smear reviewsMichael E Kallen, Rima Koka, Djordje Atanackovic
European Journal of Haematology|December 29, 2019
B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta-analysisNico Gagelmann, Francis Ayuk, Djordje Atanackovic, et al.
Current Cancer Drug Targets|September 7, 2017
Coinhibitory Molecule PD-1 as a Therapeutic Target in the Microenvironment of Multiple MyelomaDjordje Atanackovic, Tim Luetkens, Sabari Radhakrishnan, et al.
British Journal of Haematology|January 22, 2016
Chimeric Antigen Receptor (CAR) therapy for multiple myelomaDjordje Atanackovic, Sabarinath V Radhakrishnan, Neelam Bhardwaj, et al.
Clinical Immunology (Orlando, Fla.)|October 17, 2018
The role of surface molecule CD229 in Multiple MyelomaMichael Olson, Sabarinath Venniyil Radhakrishnan, Tim Luetkens, et al.
Oncoimmunology|June 23, 2017
Novel anti-myeloma immunotherapies targeting the SLAM family of receptorsSabarinath Venniyil Radhakrishnan, Neelam Bhardwaj, Tim Luetkens, et al.
Pageof 14